Mediterranean journal of rheumatology · 2025
The N-of-1 Trials and where to use them in Rheumatology.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Grammatikopoulou Maria G, Gkouvi Arriana, Tsiogkas Sotirios G, Simopoulou Theodora, Goulis Dimitrios G, Bogdanos Dimitrios P
Аннотация
OBJECTIVE: N-of-1 trials constitute single-patient, randomised, crossover and often, double-blind clinical trials, where each patient serves as his/her own control. The implementation of n-of-1 trials propels us towards the practice of patient-centric medicine, while exhibiting multiple additional advantages for rheumatology, including the identification of the most appropriate treatment for each patient, improved response, outcomes and quality of life, fewer adverse events, and reduced economic costs. The design employs similar aspects to randomised clinical trials in order to maintain scientific rigor, while producing clinically relevant treatment outcomes, tailored to each patient.
METHODS: For the purpose of this review, we searched PubMed and clinicaltrials.gov for n-of-1 trials or series conducted on patients with rheumatic diseases until August 2024.
RESULTS: N-of-1 trials can facilitate clinical decisions and evaluate the efficacy of medications, lifestyle interventions, or adjuvant treatments (i.e. for pain), while focusing on disease-specific outcomes or comorbidities (cachexia, obesity, etc.). In this review, the advantages and limitations of n-of-1 trials in rheumatology are discussed and trials performed on patients with rheumatic diseases are presented.
CONCLUSIONS: Employing the n-of-1 design in everyday clinical practice consists of the epitome of patient-centred medicine, greatly benefiting patients and clinicians, facilitating deprescribing, and reducing the economic burden of pharmacotherapy.
METHODS: For the purpose of this review, we searched PubMed and clinicaltrials.gov for n-of-1 trials or series conducted on patients with rheumatic diseases until August 2024.
RESULTS: N-of-1 trials can facilitate clinical decisions and evaluate the efficacy of medications, lifestyle interventions, or adjuvant treatments (i.e. for pain), while focusing on disease-specific outcomes or comorbidities (cachexia, obesity, etc.). In this review, the advantages and limitations of n-of-1 trials in rheumatology are discussed and trials performed on patients with rheumatic diseases are presented.
CONCLUSIONS: Employing the n-of-1 design in everyday clinical practice consists of the epitome of patient-centred medicine, greatly benefiting patients and clinicians, facilitating deprescribing, and reducing the economic burden of pharmacotherapy.